Case Study on Erythroderma Secondary to Pustular Psoriasis

Authors

  • M.Suresh Kumar Associate Professor, Department of Pharmaceutics, Avanthi Institute of Pharmaceutical Sciences
  • Abhisekhar Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram, Andhra Pradesh
  • Bonela Meghana Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Vizianagaram, Andhra Pradesh

Keywords:

Erythroderma, Pustular Psoriasis, Immunopathogenesis, Diagnostic Challenges, Severe Psoriasis, Therapeutic Strategies, Cutaneous Manifestations, Systemic Complications, Dermatological Case Study

Abstract

Erythroderma secondary to pustular psoriasis, an uncommon and intricate dermatological presentation, represents a clinical conundrum demanding meticulous examination. This case study of 45 years old female navigates the complexities surrounding this severe manifestation, elucidating the diagnostic challenges, treatment modalities, and ensuing outcomes. The evolution from classical psoriatic lesions to the erythrodermic-pustular variant involves a dynamic interplay of immunopathogenic cascades, prompting a nuanced diagnostic approach for accurate identification. Therapeutically, the condition necessitates a comprehensive strategy, balancing systemic and topical interventions to address both cutaneous and systemic manifestations. This case study contributes to the broader understanding of erythroderma secondary to pustular psoriasis, serving as a crucial reference for clinicians and researchers grappling with the intricate facets of this rare dermatological phenomenon.

Downloads

Download data is not yet available.

References

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.

Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.

Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186(4):2613-2622.

Sajja AP, Joshi A, Smith KJ. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016; 6:93-104.

Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.

Paris R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.

Published

15-12-2021

How to Cite

M, S. K., sekhar, A., & Bonela, M. (2021). Case Study on Erythroderma Secondary to Pustular Psoriasis. International Journal of Current Innovations in Advanced Research, 4(3), 5–6. Retrieved from https://ijciar.com/index.php/journal/article/view/165

Issue

Section

Case Studies & Reports